Drugs / TNX-832
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01438853 | Dec 2004 → Jul 2006 | acute lung injury, acute respiratory distress syndrome, bacterial infectious disease with sepsis | Altor BioScience | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TNX-832 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01438853 ↗ |
| Known as | ALT-836 | “TNX-832 (also referred to as ALT-836 and Sunol cH36)” NCT01438853 ↗ |
| Known as | Sunol cH36 | “TNX-832 (also referred to as ALT-836 and Sunol cH36)” NCT01438853 ↗ |
| Action | Inhibit | “TNX-832 (formerly known as Sunol-cH36), directed against human TF, which can block the pathological complications of TF-dependent thrombus formation.” NCT01438853 ↗ |
| Route | Intravenous | “Single intravenous dose of TNX-832 at 0.06, 0.08 or 0.10 mg/kg” NCT01438853 ↗ |